Riskpilot← Back to searchSign inGet full accessOSLO SMERTEKLINIKK AS
ASActiveOrg 974213400Sørkedalsveien 10D, 0369 OsloOther human health activities n.e.c. · NACE 8699Est. 19956 employees
Revenue 2024
NOK 16,8M
+29% vs 2023
EBITDA margin
6.0%
+77% vs 2023
Equity ratio
2.4%
Financial strength
Net profit 2024
NOK 795K
+107% vs 2023
| Revenue | NOK 16,8M | +29% |
| EBITDA | NOK 1M | +77% |
| Net profit | NOK 795K | +107% |
| Total assets | NOK 8,1M | +248% |
| Equity | NOK 197K | -6% |
| Employees | 6 | — |
Legal name
OSLO SMERTEKLINIKK AS
Org number
974213400
Legal form
Aksjeselskap
NACE code
8699 · Other human health activities n.e.c.
Founded
10. januar 1995
Share capital
NOK 100 000
Employees
6 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Tore bergfjord
Address
Sørkedalsveien 10D, 0369 Oslo
Phone
+4723334250
Email
post@smertemedisinskinstitutt.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 9 638 | 10 917 | 15 532 | 13 044 | 16 774 |
| Staff expenses | −4 689 | −2 765 | −3 384 | −2 525 | −892 |
| EBITDA | −17 | 1 063 | 3 547 | 572 | 1 009 |
| Depreciation & amort. | −223 | −245 | −210 | −67 | −67 |
| EBIT | −240 | 818 | 3 336 | 505 | 942 |
| Net financials | −10 | −10 | −12 | −10 | 92 |
| Profit before tax | −250 | 807 | 3 324 | 494 | 1 034 |
| Tax | −46 | 176 | 771 | 110 | 239 |
| Net profit | −204 | 632 | 2 554 | 384 | 795 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 761 | 2 608 | 3 162 | 2 333 | 8 118 |
| Equity | 1 400 | 1 132 | 1 185 | 209 | 197 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 361 | 1 476 | 1 977 | 2 124 | 7 921 |
| Total debt | 1 361 | 1 476 | 1 977 | 2 124 | 7 921 |
EBITDA margin
6.0%
This company
15.8%
Market median
-62% vs market
20202024
Equity ratio
2.4%
This company
38.2%
Market median
-94% vs market
20202024
Return on equity
404.2%
This company
18.4%
Market median
+2097% vs market
20202024
Net profit margin
4.7%
This company
8.1%
Market median
-42% vs market
20202024
Asset turnover
2.07×
This company
1.12×
Market median
+85% vs market
20202024
Debt / equity
40.27×
This company
0.62×
Market median
-6395% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TB Chief Executive Officer | Chief Executive Officer | 2025 |
| Former (1) | ||
TH Chief Executive Officer | Chief Executive Officer | 2020 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2023 | |
| Former (2) | ||
| Chairman | 2022 – 2023 | |
| Board of Directors | 2022 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 | |
| Individual | 33.33% | 33.33% | 2022 | |
| Company | 33.33% | 33.33% | 2023 | |
| Individual | 33.33% | 33.33% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Bay Invest As
OSLO SMERTEKLINIKK AS Board members of OSLO SMERTEKLINIKK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tore Hind Fagerlund | Chief Executive Officer | 0 companies |
| Tore Bergfjord | Chief Executive Officer | 0 companies |
| John Edward Creed | Chairman | 0 companies |
| Amalie Therese Knutsen Bergfjord | Chairman | 0 companies |
| Wenche Sabel | Board of Directors | 0 companies |